Skip to content
etf.net

BBP vs IBRN

Virtus Biotech ETF

BBPANYSE Arca

iShares Neuroscience and Healthcare ETF

IBRNCNYSE Arca

Overlap

Expense ratio

BBP −0.13pt a year

BBP0.34%IBRN0.47%

Avg volume · 30D

BBP 4.4×the volume

BBP11.7KIBRN2.68K

3Y return · a year

BBP +10.3pt

BBP+30.7%IBRN+20.4%

BBP vs IBRN Performance

Oct 31, 2025 – Oct 30, 2026

+39.6%BBP+11.2%IBRN

Oct 31, 2025 to Oct 30, 2026. BBP +39.6%. IBRN +11.2%. Use the arrow keys to read each point.−10%0%20%30%50%Oct 2025Apr 2026Oct 2026
Expense ratio
BBP 0.34%, better
IBRN 0.47%
Fund size
BBP $132M
IBRN $7M
1Y total return
BBP +39.6%, better
IBRN +11.2%
Yield (12M)
BBP 0.00%
IBRN 0.96%, better
Holdings
BBP 66
IBRN 71
Avg volume (30D)
BBP 11.7K sh, better
IBRN 2.68K sh
NAV per share
BBP $105.25
IBRN $32.81
52W range

ETF.net Grade

BBP: Cost 94, Risk 64, Mission 83, Tradability 31, Holdings 82, Durability 55. IBRN: Cost 56, Risk 28, Mission not scored, Tradability 25, Holdings 65, Durability 31.
Pillar letters and Scores for BBP, IBRN, with each pillar’s weight
PillarBBPIBRN
Cost30% weightA94HigherB56
Mission25% weightA83Not scored
Risk15% weightB64HigherD28
Tradability15% weightD31HigherD25
Holdings10% weightA82HigherB65
Durability5% weightB55HigherD31

Rank among Biotech & Genomics funds

How we build Categories ›
Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

Same Category. BBP and IBRN are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds
See all 17 ›

BBP ranks 4th and IBRN 10th of 17 funds in the Biotech & Genomics Category.

  1. Rank 1AXBIState Street SPDR S&P Biotech ETFScore 80
  2. Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
  3. Rank 3AIBBiShares Biotechnology ETFScore 75
  4. Rank 4ABBPVirtus Biotech ETFScore 74
  5. Rank 5BBBHVanEck Biotech ETFScore 68
  6. Rank 9CSBIOALPS Medical Breakthroughs ETFScore 44
  7. Rank 10CIBRNiShares Neuroscience and Healthcare ETFScore 43
  8. Rank 11CGNMXCorgi Genomics & Precision Medicine ETFScore 40

Our read on each fund

ETF.net Research

BBPAVirtus Biotech ETF

IBRNCiShares Neuroscience and Healthcare ETF

In short

BBP Biotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

IBRN A healthcare fund with one obsession: the brain. IBRN tracks a global index of roughly 70 drugmakers and device companies working on neurological disease, a slice most sector funds bury inside hundreds of names.

Stated mandate

BBP The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

IBRN The fund seeks to track an index of global companies advancing research and treatment of neurological disorders, providing focused exposure to healthcare innovation related to brain health.

Why people hold it

  • BBP The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
  • 0.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
  • Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
  • One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.
  • IBRN A rare single-theme cut of healthcare: brain-disease biopharma and medical devices held together, sourced globally rather than US-only.ishares.com
  • At 0.47%, it undercuts the median expense ratio of its broad healthcare peer group, unusual for a narrow theme fund.
  • Rules-based, not a stock picker: it follows a published NYSE FactSet neuro index, so the exposure you own is defined in advance.ishares.com

Worth knowing

  • BBP Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
  • Income is not the point here. The fund has not been paying distributions, so the return story is price.
  • An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.
  • IBRN Small asset base and thin trading. Spreads can run wider than on the sector's heavyweights, and that cost lands on the buyer.
  • 0.47% is several times what plain broad healthcare index funds like VHT and XLV charge. The theme is what you're paying for.
  • Roughly 70 names in one research niche, live since 2022. Trial results at a few companies can swing it more than a whole-sector fund.

Full BBP profile⁠

Full IBRN profile⁠

BBP vs IBRN Holdings

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

BBP vs IBRN Cost

Overpaying IBRN vs BBP

$2,486

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BBP 0.34%

    $6,932

  • IBRN 0.47%

    $9,418

$10,000
30 years

Cost over time

  • BBP 0.34%
  • IBRN 0.47%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K$10K051015202530IBRN $9,418BBP $6,932

Year by year

YearBBPIBRNOverpaying
10$616$847$231
20$2,386$3,261$875
30$6,932$9,418$2,486

Expense ratio

  • 0.34%BBP, cheaper
  • 0.47%IBRN
  • Middle half of Biotech & Genomics funds
  • Median 0.47%

BBP 2nd cheapest of 17 funds

IBRN 8th cheapest of 17 funds

BBP vs IBRN Dividends

Last 12 months to Oct 30, 2026
Yield (12M)
BBP 0.00%
IBRN 0.96%, better
Payout (12M)
BBP None
IBRN $0.32
Last payment
BBP No data
IBRN $0.32
Ex-dividend
BBP No data
IBRN Dec 16, 2025
Paid on
BBP No data
IBRN Dec 19, 2025
Frequency
BBP No data
IBRN Annual

Distribution history

Per share, 2017 to 2026, same scale for both

BBP1 paymentAll BBP payments⁠
One bar per payment. 1 payment from 2017 to 2026 YTD. Dec 20, 2017 $0.07. Use the arrow keys to read each point.$0$0.252017202020232026YTD
IBRNAnnual · 4 paymentsAll IBRN payments⁠
One bar per payment. 4 payments from 2017 to 2026 YTD. Jun 7, 2023 $0.0082; Dec 20, 2023 $0.0063; Dec 17, 2024 $0.10; Dec 16, 2025 $0.32. Use the arrow keys to read each point.$0$0.252017202020232026YTD

BBP vs IBRN Risk

Fall from peak · 5 years

This chart needs five years of history for both funds.

Risk facts

VolatilityStd dev, 3 years
BBP 18.7%, betterIBRN 23.6%
Return per unit of riskSharpe ratio, 3 years
BBP 1.30, betterIBRN 0.71
Worst fallMax drawdown, 5 years
BBP −37.8%IBRN −35.4%since Aug 2022
Market sensitivityBeta, 5 years
BBP 0.77IBRN 0.87

Popular comparisons

  • BBPAvsXBIA

    Virtus Biotech ETF · State Street SPDR S&P Biotech ETF

    Expense ratio
    0.34% · 0.35%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • IBRNCvsXBIA

    iShares Neuroscience and Healthcare ETF · State Street SPDR S&P Biotech ETF

    Expense ratio
    0.47% · 0.35%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBPAvsIBBQA

    Virtus Biotech ETF · Invesco Nasdaq Biotechnology ETF

    Expense ratio
    0.34% · 0.19%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • IBRNCvsIBBQA

    iShares Neuroscience and Healthcare ETF · Invesco Nasdaq Biotechnology ETF

    Expense ratio
    0.47% · 0.19%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBPAvsIBBA

    Virtus Biotech ETF · iShares Biotechnology ETF

    Expense ratio
    0.34% · 0.44%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • IBRNCvsIBBA

    iShares Neuroscience and Healthcare ETF · iShares Biotechnology ETF

    Expense ratio
    0.47% · 0.44%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.